, GlobeNewswire
Addex Regains Rights to Parkinson's Drug Candidates from Merck
Addex Pharmaceuticals /
Addex Regains Rights to Parkinson's Drug Candidates from Merck
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Geneva, Switzerland, 2 September 2011 - Addex Pharmaceuticals (SIX:ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that it will regain all rights to its
metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM)
program from Merck, known as MSD outside the United States and Canada, due to
further pipeline prioritization.
"We continue to strongly believe that mGluR4 is a highly attractive target for
treating Parkinson's and other serious diseases," said Bharatt Chowrira, CEO of
Addex. "We recognize the substantial challenges for the pharmaceutical industry
today and we thank our partner for this collaboration and the significant
advances we made together in targeting this important receptor. We remain
committed to pursuing mGluR4 PAM for Parkinson's and other diseases."
Under the agreement, Addex will regain rights to intellectual property and know-
how and can pursue the program independently.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops an emerging
class of small molecule drugs, called allosteric modulators, which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The company uses
its proprietary discovery platform to address receptors and other proteins that
are recognized as attractive targets for modulation of important diseases with
unmet medical needs. The Company's two lead products are being investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and, ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals, Inc., to treat schizophrenia. Addex also is advancing several
preclinical programs including: mGluR2 NAM for treating Alzheimer's disease and
depression; mGluR4 PAM for Parkinson's and other diseases; GLP1R PAM for type 2
diabetes; FSHR NAM for endometriosis and benign prostatic hyperplasia; and
GABABR PAM for chronic pain, urinary incontinence and other disorders. In
addition, Addex has discovery programs to identify allosteric modulators of:
receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating
neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's
diseases); TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g.
rheumatoid arthritis); and, interleukin receptor family, such as IL1R1 NAM for
gout and type II diabetes.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11 Direct
+41 22 884 15 55 General
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, GABABR, FSHR, GLP1R, TNFR1, IL1R1, RTK, TrkB or other therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR, GLP1R,
TNFR1, IL1R1, RTK, TrkB or other therapeutics targets will be approved for sale
in any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR, GLP1R,
TNFR1, IL1R1, RTK, TrkB or other therapeutic targets will achieve any particular
levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,
FSHR, GLP1R, TNFR1, IL1R1, RTK, TrkB or other therapeutic targets could be
affected by, among other things, unexpected actions by our partners, unexpected
regulatory actions or delays or government regulation generally; unexpected
clinical trial results, including unexpected new clinical data and unexpected
additional analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; the company's ability
to obtain or maintain patent or other proprietary intellectual property
protection. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Addex
Pharmaceuticals Ltd is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise, except as may be required by applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1543752]
Addex Regains Rights to Parkinson's Drug Candidates from Merck
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Geneva, Switzerland, 2 September 2011 - Addex Pharmaceuticals (SIX:ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that it will regain all rights to its
metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM)
program from Merck, known as MSD outside the United States and Canada, due to
further pipeline prioritization.
"We continue to strongly believe that mGluR4 is a highly attractive target for
treating Parkinson's and other serious diseases," said Bharatt Chowrira, CEO of
Addex. "We recognize the substantial challenges for the pharmaceutical industry
today and we thank our partner for this collaboration and the significant
advances we made together in targeting this important receptor. We remain
committed to pursuing mGluR4 PAM for Parkinson's and other diseases."
Under the agreement, Addex will regain rights to intellectual property and know-
how and can pursue the program independently.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops an emerging
class of small molecule drugs, called allosteric modulators, which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The company uses
its proprietary discovery platform to address receptors and other proteins that
are recognized as attractive targets for modulation of important diseases with
unmet medical needs. The Company's two lead products are being investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and, ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals, Inc., to treat schizophrenia. Addex also is advancing several
preclinical programs including: mGluR2 NAM for treating Alzheimer's disease and
depression; mGluR4 PAM for Parkinson's and other diseases; GLP1R PAM for type 2
diabetes; FSHR NAM for endometriosis and benign prostatic hyperplasia; and
GABABR PAM for chronic pain, urinary incontinence and other disorders. In
addition, Addex has discovery programs to identify allosteric modulators of:
receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating
neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's
diseases); TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g.
rheumatoid arthritis); and, interleukin receptor family, such as IL1R1 NAM for
gout and type II diabetes.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11 Direct
+41 22 884 15 55 General
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, GABABR, FSHR, GLP1R, TNFR1, IL1R1, RTK, TrkB or other therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR, GLP1R,
TNFR1, IL1R1, RTK, TrkB or other therapeutics targets will be approved for sale
in any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR, GLP1R,
TNFR1, IL1R1, RTK, TrkB or other therapeutic targets will achieve any particular
levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,
FSHR, GLP1R, TNFR1, IL1R1, RTK, TrkB or other therapeutic targets could be
affected by, among other things, unexpected actions by our partners, unexpected
regulatory actions or delays or government regulation generally; unexpected
clinical trial results, including unexpected new clinical data and unexpected
additional analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; the company's ability
to obtain or maintain patent or other proprietary intellectual property
protection. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Addex
Pharmaceuticals Ltd is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise, except as may be required by applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1543752]
Relevante Links: Addex Therapeutics Ltd